The serum ANGPTL4 levels in the HL-Pro group (27.94 (18.90, 53.72) ng/ml) did not differ significantly from those in the Con group (36.82 ± 17.03 ng/ml) (P > 0.05); however, the serum ANGPTL4 levels of the HL-NPro group (53.32 ± 24.01 ng/ml) increased significantly (P < 0.05), while there was a significant decrease of the same in the NHL-Pro group (23.56 ± 9.30 ng/ml) (P < 0.05). The gene discussed is ANGPTL4; the disease is non-Hodgkin lymphoma.